Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BN82451B in Male Patients With Huntington's Disease
NCT02231580Phase 2Terminated
- Sponsor
- Ipsen
- Start
- Sep 2014
- Primary completion
- Mar 2016
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial in Huntington's disease (HD) comparing BN82451B with Placebo (2 arms). Primary endpoint: Treatment Emergent Adverse Events. Started Sep 2014; status: terminated.
02
Drugs
BN-82451
03
Conditions
Huntington's disease (HD)
Beyond the preview
Go deeper on NCT02231580.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02231580.